Verve Therapeutics (VERV) Reported Results From its Heart-2 Phase 1b Trial for VERVE-102
Verve Therapeutics, Inc. (NASDAQ:VERV) is one of the Stocks With Huge Catalysts on the Horizon. On April 14, Verve Therapeutics, Inc.
Verve Therapeutics Inc. (VERV)
This company is not actively trading or the ticker does belong to another company in our database now.
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Bailard Inc Thomas Bailard | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $6.26 | 76,000 | $475,760.00 | 342,509 | 2024-05-14 | Filing | |
| $10.00 | 1,800,000 | $18,000,000.00 | 1,800,000 | 2023-12-01 | Filing | |
| $12.15 | 10,000 | $121,526.00 | 18,700 | 2022-05-12 | Filing | |
| $21.38 | 4,000 | $85,535.20 | 8,700 | 2022-03-15 | Filing | |
| $32.10 | 4,000 | $128,419.60 | 170,722 | 2021-12-02 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.15 | 9,822 | $40,761.30 | 346,686 | 2025-04-02 | Filing | |
| $4.15 | 2,777 | $11,524.55 | 17,420 | 2025-04-02 | Filing | |
| $4.15 | 2,681 | $11,126.15 | 348,828 | 2025-04-02 | Filing | |
| $4.15 | 3,235 | $13,425.25 | 14,226 | 2025-04-02 | Filing | |
| $4.15 | 3,350 | $13,902.50 | 13,280 | 2025-04-02 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 0 | $0 | 0% | |
| 2. | 0 | $0 | 0% | |
| 3. | 0 | $0 | 0% | |
| 4. | 0 | $0 | 0% | |
| 5. | 0 | $0 | 0% |
News See All
10 Stocks With Huge Catalysts on the Horizon
The August 1 tariff deal is approaching; however, the market seems to have gotten used to the tariff headlines.
Verve Therapeutics, Inc. (VERV): A Bull Case Theory
We came across a bullish thesis on Verve Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this article, we will summarize the bulls’ thesis on VERV.
Lilly To Acquire Verve For One-Time Cardiovascular Treatments
Verve Therapeutics, Inc. (NASDAQ:VERV) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Eli Lilly and Company will buy Verve Therapeutics, Inc.
11 Best Genomics Stocks to Buy According to Hedge Funds
Genomics is the study of genes and how they operate.
8 Best Gene-Editing Stocks to Buy
Gene editing is an advanced medical technique within gene therapy that involves precisely modifying an individual’s DNA to treat or prevent diseases.
Top 11 CRISPR Stocks to Invest In
The pharmaceutical industry is buzzing with innovation, driven by the need for new treatments, tackling unmet medical challenges, and leveraging cutting-edge technologies like pharmacogenomics, digital...
10 Best Gene Therapy Stocks to Buy Right Now
Gene therapy is referred to as a medical technique that involves modifying or manipulating genes to treat or prevent disease.
7 Best NASDAQ Stocks Under $5
A Yahoo Finance report on September 28 reveals that consumers are beginning to feel the effects of a cooling labor market, according to the latest Consumer Confidence Index, which shows a narrowing gap...
10 Worst ARK Stocks To Buy According To Short Sellers
Investing comes in all sizes and flavors. For the risk averse investors that are looking for steady payouts or long term stability, value and dividend paying stocks are the way to go.